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B R I E F  R E P O R T
Point-of-Care test screening versus Case finding for paediatric 
coeliac disease: A pragmatic study in primary care
In paediatric coeliac disease (CD), symptoms may not be a reliable 
factor in the diagnosis of coeliac disease as described by Rosen et al,1 
and thus, recommendations for reviewing CD screening criteria 
were suggested.2 Apart from the costs, an important limiting factor 
in paediatric population mass screening using conventional immu-
noglobulin (Ig) A tissue transglutaminase (tTGIgA) may be the low 
compliance of asymptomatic children to be referred for testing. On 
the other hand, the alternative approach, the CF strategy, relies on 
selecting the individuals to be tested for CD, in the presence of con-
ditions known to be associated with CD, by the family paediatrician. 
However, search for CD would be more effective if family paediatri-
cians (FPs) were provided with a less invasive, cheap point-of-care 
test (POCT), to administer to children they have in care.
Recently, the need to estimate the benefits and the economic 
aspects of CD screening was emphasised.3
The aim of the present prospective study was to evaluate diag-
nostic yield and cost consequences of a point-of-care test-based 
screening regardless of symptoms versus case finding, for the detec-
tion of coeliac disease in paediatric primary care.
Once having obtained informed consent from the family and 
children, 44 FPs offered a POCT (the ‘new-generation’ Biocard™ co-
eliac test, AniBiotech®), for tTG IgA to children that consecutively 
attended their offices.
Exclusion criteria were as follows: age < 1 year, a previous di-
agnosis of CD, a gluten-free diet, use of medicines that can affect 
results, such as immunosuppressors, a serological test for CD in the 
last 12 months or fever at the moment of the visit.
Ethical approval was obtained from the Ethics Committee of the 
University Hospital where the Celiac Regional Center coordinating 
the study is allocated. The study has been performed in accordance 
with the ethical standards of the Declaration of Helsinki of 1975 as 
revised in 1983.
The POCT, performed as previously described,4 is positive if two 
lines are seen and negative if only the control line (with an antihu-
man IgA antibody) forms. If no line is visible, IgA deficiency should 
be suspected.
POCT was performed by paediatricians (70 tests each) partici-
pating in the study.
Symptoms and conditions associated with CD suggested by 
ESPGHAN guidelines5 were recorded, while parents and FPs were 
blinded to the results of the POCT.
All positive POCT and no line subjects were referred to coeliac 
centres to undergo conventional enzyme-linked immunosorbent 
assay for tTG IgA or IgG tissue transglutaminase antibodies, respec-
tively, with one of the kits recommended by ESPGHAN.5 Serum total 
IgA was also measured in subjects with no line at POCT, in view of 
the suspicion of having IgA deficiency. According to the study design 
as approved by Ethics Committee, only symptomatic subjects at CF 
with negative POCT but not the asymptomatic ones were referred 
to coeliac centre to have a paediatric gastroenterology consultation 
and conventional tTG IgA, and thus, the negative predictive value of 
POCT was not calculated.
In subjects with positive serology, a histological examination and 
diagnosis were made according to ESPGHAN guidelines.5
To assess the cost consequences of the different strategies, 
through a bottom-up approach and to regional health system per-
spective, only direct medical costs actually reimbursed by the region 
were taken into account. Two sensitivity analyses were developed 
for evaluating the strength of the results. In the first one, a cost 
of + 20% for POCT was used, while in the second one, to compare 
POCT screening strategy vs CF, a cost for each FP visit of €15.44 
was added to every patient in the CF.
The results are shown in the diagram of participants (mean age 
5.7 years; age range 12 months-14 years, F/M ratio: 1.16) through 
the study in Figure 1.
Eleven children, detected by POCT screening, would not have 
been detected as having CD because they did not have symptoms 
and were brought to paediatricians’ offices for routine healthy 
controls.
Seventy tests showed no line. In this group, none had IgA defi-
ciency and none was diagnosed as having CD (Figure 1).
In the base case scenario, a mean cost for each diagnosed CD 
patient of €683.30 was estimated. Instead, for CF strategy a mean 
cost of €790.78 per diagnosed CD patient was assessed. These 
costs increased to €786.65, in the first sensitivity analysis, and 
to €11 002, in the second sensitivity analysis, for POCT and CF, 
respectively.
Our results suggest that if a case finding strategy only had been 
used, 11 patients disclosed by screening would have been missed. In 
view of this, it appears that POCT screening is a superior strategy 
to aid diagnosis of CD in children. These results are in keeping with 
those of Rosen et al.1
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Regarding the cost consequences, the POCT strategy, despite 
being costlier than CF, showed a 14% lower cost for each patient 
diagnosed with CD.
We are aware that the most important limitation of the present 
study is that we were not able to calculate the predictive negative 
value of POCT because, according to the study design as approved 
by ethics committee, we did not refer asymptomatic children with 
POCT negative to coeliac centres, and only 75% of POCT negative 
symptomatic children underwent conventional serology due to re-
fusal after the POCT turned-out to be negative. For this reason, we 
suggest that paediatricians utilise POCT in asymptomatic children 
only and refer children with clinical suspicion of CD for undergoing 
conventional serology; otherwise, testing for CD might be slowed 
down by a negative POCT.
Despite its low positive predictive value (47.1%), balanced by the 
very low cost, and even if ‘no line result’ does not correspond to IgA 
deficiency (but no coeliac was missed), POCT may be a useful and 
economic option for screening asymptomatic children and seems 
more convenient than a case finding strategy to bridge the diagnos-
tic gap of CD in children.
These results may become more relevant utilising a next-gener-
ation POCT with better positive predictive value. More studies are 
needed to assess whether our screening strategy may be applied in 
other regions and countries.
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